GSK Looks To Capitalize On AstraZeneca’s Anemia Drug Knock-Back
Safety Profile Will Be Battleground
Executive Summary
AstraZeneca and FibroGen hit another safety roadblock with roxadustat, while GSK is hoping it might catch up with its rivals in the US.